Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

r a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

COMPANY CONTACT: INVESTOR RELATIONS CONTACTS

Spectranetics Corporation Lippert/Heilshorn & Associates, Inc.

Guy Childs, Chief Financial Officer Bruce Voss/Don Markley

(719) 633-8333 (310) 691-7100

http://www.spectranetics.com http://www.lhai.com

MEDIA RELATIONS CONTACT:

Schwartz Communications, Inc.

Stacey Holifield

(781) 684-0770

spectranetics@schwartz-pr.com


'/>"/>
SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Cardiac Dimensions ® , Inc. ... the TITAN II clinical trial of its enhanced ... improvements in mitral regurgitation, functional improvement, quality of ... and efficacy data, which was consistent with previous ... at the 26 th annual Transcatheter Cardiovascular ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. ... Phase 2 clinical program of NP001 for the treatment ... disease) are being highlighted today in an oral ... Research Group , being held in Bloomington, ... post hoc  analysis, administration of a high dose of ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. 17, 2014 ... a partnership in the fight against sarcoma. Under ... Alliance Suzanne Renee Leider Memorial Assistance Fund. ... to reimburse sarcoma patients for expenses directly related ... specialist. Scientific literature reinforces the importance of this ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
... MOUNTAIN VIEW, Calif., Jan. 26, 2012 Omnicell, Inc. (NASDAQ: ... healthcare facilities, today announced results for its fourth quarter and ... Revenue for the fourth quarter of 2011 was $62.9 million, ... 2010 and down $1.5 million or 2.3% from the third ...
... 2012 Amgen (NASDAQ: AMGN ) reported total ... to $3,973 million versus $3,841 million in the fourth quarter ... 4 percent to $15,582 million from $15,053 million in 2010. ... the fourth quarter of 2011, an increase of 3 percent ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full Year 2011 Results 2Omnicell Announces Fourth Quarter and Full Year 2011 Results 3Omnicell Announces Fourth Quarter and Full Year 2011 Results 4Omnicell Announces Fourth Quarter and Full Year 2011 Results 5Omnicell Announces Fourth Quarter and Full Year 2011 Results 6Omnicell Announces Fourth Quarter and Full Year 2011 Results 7Omnicell Announces Fourth Quarter and Full Year 2011 Results 8Omnicell Announces Fourth Quarter and Full Year 2011 Results 9Omnicell Announces Fourth Quarter and Full Year 2011 Results 10Omnicell Announces Fourth Quarter and Full Year 2011 Results 11Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 2Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 3Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 4Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 5Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 6Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 7Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 8Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 9Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 10Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 11Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 12Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 13Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 14Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 15Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 16Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 17Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 18Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 19
(Date:9/17/2014)... Historically, spaceflight has been reserved for the very ... meet the highest physical and psychological standards to ... the advent of commercial spaceflight, average people can ... has had very little information about what medical ... in the spaceflight environment, as most medical conditions ...
(Date:9/17/2014)... People who struggle to distinguish between a business strategy and ... get the answer by reading Per Wickstrom’s latest blog post. ... business plan and a business strategy are both strategic – ... way I view it is that a business plan is ... two.” , According to the blog post, a business ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
(Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Positive messages ... some people kick the habit, a new study suggests. ... responded better to "loss-framed" messages about the harmful effects ... quit whenever they want benefit more from "gain-framed," or ... The researchers concluded that using a mix of ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... University,s Physical Activity and Public Health Laboratory, active commuting ... can be an easy, effective and efficient way to ... Wittman, a K-State senior in kinesiology, Olathe, worked with ... of kinesiology, on the active commuting research. The project ...
... April 13 Mylan Inc. (Nasdaq: MYL ... banker,Andrew G. Cuneo as vice president of Global Business ... and strategic,efforts in close alignment with the company,s executive ... Chairman and CEO Robert J. Coury said: "Drew brings ...
... 13 Lionbridge,Technologies, Inc. (Nasdaq: ... testing,and development services today announced an alliance ... Enterprise Content Management (ECM) software,designed to ensure ... management solutions for pharmaceutical companies and other,organizations. ...
... could one day quickly detect if treatment is working, study ... technique that can detect subtle changes in cancer cells contained ... tissue may one day be used by doctors to better ... , "Currently, we don,t know what,s going on in a ...
... Though a high-fiber diet has long been considered good ... Medical College of Georgia researchers have discovered a reason ... Researchers report in the April issue of Cancer ... butyrate, a metabolite produced by fiber-eating bacteria in the ...
... 15th, there will be a,Capitol Hill briefing called ... and Mental Illness." Author and award winning ... HELP USA,Lamp Community, the National Alliance on Mental ... H.O.M.E. have join forces to host this,important briefing. ...
Cached Medicine News:Health News:Survey research looks at attitudes, obstacles to walking and biking to work 2Health News:Survey research looks at attitudes, obstacles to walking and biking to work 3Health News:Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development 2Health News:Lionbridge Announces Partnership with Open Text to Streamline Regulatory Compliance Solutions for Pharmaceutical Companies 2Health News:A Drop of Blood May Help Assess Cancer Therapy 2Health News:Colon cancer shuts down receptor that could shut it down 2Health News:Colon cancer shuts down receptor that could shut it down 3Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 2Health News:Capitol Hill Briefing Scheduled for April 15th About Homelessness and Mental Illness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: